elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Lab
Pricing
Log in
Sign up
Home
/
Subjects
/
Denosumab
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Denosumab
RIS
0.003
(Research Intensity Score)
Papers
206
Top papers
Targeting strategies for bone diseases: signaling pathways and clinical studies
2023 · 154 citations
Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial
2025 · 44 citations
Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review
2023 · 72 citations
Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS)
2023 · 59 citations
Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis
2019 · 323 citations
2024 Royal Australian College of General Practitioners and Healthy Bones Australia guideline for osteoporosis management and fracture prevention in postmenopausal women and men over 50 years of age
2025 · 18 citations
Multifunctional gold nanoparticles for osteoporosis: synthesis, mechanism and therapeutic applications
2023 · 28 citations
Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art
2021 · 65 citations
Bone-Targeted Platinum Nanoframework Prevents Postmenopausal Osteoporosis via Transmembrane Protein 16A Channel Blockade and Reactive Oxygen Species Scavenging
2025 · 6 citations
Newest papers
Age-related differences in BMD response during three years of denosumab treatment
2026
Keeping bone resorption markers very low for 1 year after denosumab prevents bone loss at 2 years: the ReoLaus study
2026
Bone Health in Prostate Cancer: Two Clinical Paradigms and the Evolving Role of Bone-Protecting Agents
2026
Atypical Femoral Fractures over the Decades: Bisphosphonates Still Dominate the Landscape
2026
Progress on novel compounds for the treatment of bone metabolism-related disorders: focus on osteoporosis and beyond
2026
Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801)
2026
Chronic kidney disease: from mineral dysregulation to bone and cardiovascular disease
2026
Osteoprotegerin is strongly associated with calcium and magnesium in seminal fluid but not affected by denosumab
2026
Association between Denosumab Therapy and Hypocalcemia: Influence of Concomitant Gastric Acid–Suppressive Agents and Other Clinical Parameters
2026
Browse all papers →
Denosumab's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Denosumab's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link